Loading stock data…
$33.30+0.41 (+1.26%)
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma.
Castle Biosciences, Inc. in the Healthcare sector is trading at $33.30 with a market capitalization of $1.0B. Wall Street consensus targets $45.22 (9 analysts), implying a +35.8% move over the next 12 months. The stock is currently 25% below its 52-week high of $44.28, remaining 15.4% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $103.55M↑ | $83.68M↓ | $87.01M↑ | $83.04M↓ | $86.19M |
| Gross Profit | $79.85M↑ | $63.15M↓ | $68.69M↑ | $64.34M↓ | $68.56M |
| Operating Income | -$3.07M↑ | -$18.41M↓ | -$3.83M↑ | -$6.80M↓ | -$4.25M |
| Net Income | -$2.06M↑ | -$14.52M↓ | -$2.33M↓ | -$501,000↓ | $4.52M |
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, ...